Mojgan Mirghafourvand, Sakineh Mohammad Alizadeh Charandabi, Yousef Javadzadeh, Parivash Ahmadpour,
Volume 21, Issue 1 (6-2015)
Abstract
Background & Aim: Premenopausal syndrome affects daily activities of many women. This study aimed to compare the effects of Vitexagnus and Flaxseed on premenstrual symptoms in women referred to health centers of Tabriz from October 2013 to September 2014 .
Methods & Materials: This randomized controlled trial was conducted among 159 women suffered from premenstrual syndrome (PMS). The PMS was measured using the premenstrual assessment form (PAF) . The participants were allocated into three groups (n=53 per group) using block randomization. The group I received 25 grams/d Flaxseed powder and placebo of the Vitexagnus group II received 3.2-4.8 mg/d Vitexagnus tablets and placebo of the Flaxseed and the control group received both placeboes. The PAF was completed at baseline and 1 and 2 month after the intervention. Data were analyzed using the general linear model .
Results: The PMS improved significantly in both intervention groups during the first and the second month after the intervention. In the Vitexagnus and Flaxseed groups, the mean total PMS score were significantly lower than that in the control group at the first months after the intervention (adjusted mean difference: -3.3 (95% CI: -4.0 to -2.1) -4.3 (-5.5 to -3.0), respectively). In the second month after the intervention, the mean total PMS score was -5.8 (-7.0 to -4.7) in the Vitexagnus group and -6.6 (-8.1 to -5.7) in the Flaxseed group. There was no significant difference between the Vitexagnus and Flaxseed groups in terms of the PMS score .
Conclusion: According to the results of this study, Flaxseed and Vitexagnus are effective in improving PMS .
Atye Babaii, Mohammad Abbasinia, Bahman Aghaei, Maryam Karimi, Ali Javadzadeh, Fatemeh Aliasl, Seyed Kazem Mousavi,
Volume 31, Issue 1 (4-2025)
Abstract
Background & Aim: Sleep disorders are common among patients hospitalized in cardiac care units (CCUs), potentially impeding treatment outcomes and recovery processes. Aromatherapy has historically been employed to alleviate sleep disorders. This study aimed to determine the effect of geranium aromatherapy on sleep quality in patients hospitalized in CCUs.
Methods & Materials: This randomized controlled trial was conducted in 2022 at Shahid Beheshti Hospital in Qom. Seventy-two patients were selected via convenience sampling and randomly assigned to either the control group (n=35) or the intervention group (n=35). The intervention involved inhalation of geranium scent for three consecutive nights, whereas the control group received no such intervention. Data collection utilized the Richards-Campbell Sleep Questionnaire (RCSQ), administered pre- and post-intervention. Data analysis was performed using SPSS version 21, employing descriptive and inferential statistical methods.
Results: No significant differences were observed between groups regarding baseline demographic characteristics (P>0.05). Prior to the intervention, the mean sleep quality scores were 48.26±6.89 in the control group and 53.20±14.15 in the intervention group (P=0.110). Post-intervention, scores were 50.18±35.43 and 84.21±28.86, respectively, with the changes within groups being statistically significant (P<0.001). Across all dimensions of sleep quality, the intervention group demonstrated significantly better outcomes than the control group (P<0.05).
Conclusion: The results of this study showed that geranium aromatherapy appears to effectively improve sleep quality among CCU patients. Therefore, it is suggested that this method be used alongside existing treatments to enhance sleep quality in these patients.
